文章：

膀胱癌生物学及治疗进展

Advances in bladder cancer biology and therapy

原文发布日期：2020-12-02

DOI: 10.1038/s41568-020-00313-1

类型: Review Article

开放获取: 否

英文摘要：

The field of research in bladder cancer has seen significant advances in recent years. Next-generation sequencing has identified the genes most mutated in bladder cancer. This wealth of information allowed the definition of driver mutations, and identification of actionable therapeutic targets, as well as a clearer picture of patient prognosis and therapeutic direction. In a similar vein, our understanding of the cellular aspects of bladder cancer has grown. The identification of the cellular geography and the populations of different cell types and quantifications of normal and abnormal cell types in tumours provide a better prediction of therapeutic response. Non-invasive methods of diagnosis, including liquid biopsies, have seen major advances as well. These methods will likely find considerable utility in assessing minimal residual disease following treatment and for early-stage diagnosis. A significant therapeutic impact on patients with bladder cancer is found in the use of immune checkpoint inhibitor therapeutics. These therapeutics have been shown to cure some patients with bladder cancer and significantly decrease adverse events. These developments provide patients with better monitoring opportunities, unique therapeutic options and greater hope for prolonged survival.

摘要翻译： 

膀胱癌研究领域近年来取得显著进展。新一代测序技术已识别出膀胱癌中突变最频繁的基因。这些海量信息使得驱动突变的界定、可操作治疗靶点的识别成为可能，同时为患者预后和治疗方向提供了更清晰的图景。在细胞层面，我们对膀胱癌的认知也日益深入。通过界定肿瘤细胞空间结构、不同细胞类型群体分布以及正常与异常细胞类型的定量分析，能够更准确预测治疗反应。无创诊断方法（包括液体活检）也取得重大突破，这些技术在评估治疗后微小残留病灶和早期诊断方面具有重要应用潜力。免疫检查点抑制剂疗法对膀胱癌患者产生了显著治疗效果，临床证实该疗法可治愈部分膀胱癌患者并显著减少不良事件。这些进展为患者提供了更优的监测手段、特色治疗方案以及延长生存期的更大希望。

原文链接：

Advances in bladder cancer biology and therapy